
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis is poised for strong growth with their expanding sales force, positive financials, and partnerships with leading companies. Their recent Medicare coverage for their NeXT Personal MRD test and potential partnerships with Tempus and Moderna further solidify their position in the market. However, competition and regulatory challenges may pose risks for the company's future success.
Bears say
Personalis is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The negative outlook is driven by concerns over the company's high dependence on its biopharma business and the potential impact of volatility in ordering patterns and funding from the U.S. Department of Veterinary Affairs. Additionally, the company's recent cross-licensing deal with Myriad Genetics for its intellectual property could indicate challenges in competing in the clinical MRD testing market. The company's recent publication of results from its early stage breast cancer study is promising, but it remains to be seen if it will translate into significant revenue growth.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares